News | August 01, 2014

How to Implant the SynCardia Total Artificial Heart Detailed in New Paper

Doctors at Virginia Commonwealth University Medical Center discuss the benefits and use of the SynCardia Total Artificial Heart in a PubMed indexed case report and video that includes implant surgery of 60-year-old man

SynCardia Total Artificial Heart Implant VAD Heart Failure Treatments

Daniel G. Tang, Virginia Commonwealth University Medical Center assistant professor of cardiothoracic surgery, explains the SynCardia Total Artificial Heart implantation procedure.

August 1, 2014 — For the first time, cardiac surgeons, medical professionals and the public can watch the implantation of the SynCardia temporary Total Artificial Heart in a peer reviewed case report paper and matching video posted on the Journal of Visualized Experiments website.

The 16-minute video accompanies “Implantation of the SynCardia Total Artificial Heart,” a July 18, 2014 paper by cardiac surgeons at Virginia Commonwealth University Medical Center.

The paper and video both describe the case of a 60-year-old male with hypertrophic cardiomyopathy. Both detail the implantation surgery. They also discuss perioperative complications, postoperative care and selection of good candidates for the procedure.

“Patients often present with cardiogenic shock and multi-system organ dysfunction,” according to the paper by Daniel G. Tang, Keyur B. Shah, Michael L. Hess and Vigneshwar B. Kasirajan. “Excision of both ventricles and orthotopic replacement with the [SynCardia Total Artificial Heart] is an effective…therapy for rapid restoration of blood flow and resuscitation.”

Heart failure patients who are extremely sick can get a second chance at life with the SynCardia Total Artificial Heart. It is the only approved device that eliminates the source of end-stage biventricular (both sides) heart failure in which the native heart ventricles can no longer can pump enough blood for the patient to survive.

“The main advantage of the Total Artificial Heart over left ventricle assist devices [LVADs] is the [SynCardia Total Artificial Heart] allows for high-flow biventricular support,” Tang, VCU assistant professor of cardiothoracic surgery, said in the video, “as well as the ability to treat a wide range of complex cardiac pathology that may not be ideally treated with isolated [LVAD] support.”

The SynCardia Total Artificial Heart is becoming the standard of care for addressing end-stage biventricular heart failure. “Refinements in the current generation SynCardia [Total Artificial Heart], patient selection, management of pericardial space, as well as peri-operative management of the patients, have led to a marked improvement in patient outcomes,” Tang said.

More than 1,300 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.

For more information: www.syncardia.com

Related Content

Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Heartware HVAD recall for its ventricular assist device from Medtronic
Feature | Ventricular Assist Devices (VAD) | May 05, 2017
May 5, 2017 — Medtronic Mechanical Circulatory Support is expanding its recall of its HeartWare Ventricular Assist De
Videos | Ventricular Assist Devices (VAD) | April 14, 2017
A discussion with William O'Neill, M.D., FACC, FSCAI, medical director of the Center for Structural Heart Disease at
Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017
Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing...
Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017
Metro Detroit cardiologists from five health systems have joined together to increase residents’ survival rate from...
Impella 2.5 heart pump, high-risk PCI, HRPCI, acute kidney injury risk, AKI, Circulation Research study, Abiomed
News | Ventricular Assist Devices (VAD) | March 09, 2017
A new study published in Circulation Research finds use of hemodynamic support with the Impella 2.5 heart pump during...
James Ward, LVAD surgery, left ventricular assist device, UAB, University of Alabama at Birmingham
News | Ventricular Assist Devices (VAD) | March 08, 2017
Congestive heart failure patients at the University of Alabama at Birmingham (UAB) now have reason for optimism with a...
Overlay Init